Lincoln Pharmaceuticals Limited (BOM:531633)
India · Delayed Price · Currency is INR 646.45
-4.35 (-0.67%)
At close: Jun 16, 2026
Lincoln Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 878.94 | 823.46 | 933.05 | 728.99 | 693.55 |
Depreciation & Amortization | 145 | 127.98 | 105.19 | 90.55 | 79.53 |
Other Amortization | - | 1.01 | 1.06 | 1.11 | 1.35 |
Loss (Gain) From Sale of Assets | -1.58 | 1.4 | 2.76 | -0.76 | 1.3 |
Loss (Gain) From Sale of Investments | -19.48 | -61.2 | -227.85 | -51.35 | -36.1 |
Provision & Write-off of Bad Debts | -8.75 | 1.49 | 6.5 | -1.78 | 5.27 |
Other Operating Activities | -26.11 | -55.69 | -27.36 | -60.42 | -7.61 |
Change in Accounts Receivable | 58.25 | -47.79 | -260.86 | -202.12 | -31.19 |
Change in Inventory | -14.28 | -15.09 | -71.4 | 27.14 | -261.29 |
Change in Accounts Payable | -0.85 | 125.08 | 215.73 | -205.14 | 145.93 |
Change in Other Net Operating Assets | 52.45 | 29.5 | -44.64 | 66.39 | 170.6 |
Operating Cash Flow | 1,064 | 930.16 | 632.17 | 392.62 | 761.32 |
Operating Cash Flow Growth | 14.34% | 47.14% | 61.01% | -48.43% | 9.91% |
Capital Expenditures | -254.28 | -190.29 | -394.76 | -142.59 | -455.25 |
Sale of Property, Plant & Equipment | 15.19 | 1.22 | 0.9 | 7.06 | 0.79 |
Sale (Purchase) of Intangibles | -6.12 | -2.15 | -1.37 | -0.23 | - |
Investment in Securities | -328.74 | -286.83 | -248.05 | 106.14 | -125.3 |
Other Investing Activities | -3.84 | 25.38 | 305.48 | -140.95 | -81.26 |
Investing Cash Flow | -984.04 | -789.47 | -573.41 | -366.43 | -780.8 |
Short-Term Debt Issued | 44.22 | 684.2 | 200 | 193.57 | 20 |
Total Debt Issued | 44.22 | 684.2 | 200 | 193.57 | 20 |
Short-Term Debt Repaid | - | -694.17 | -209.02 | -195.02 | - |
Long-Term Debt Repaid | - | - | - | - | -5.2 |
Total Debt Repaid | - | -694.17 | -209.02 | -195.02 | -5.2 |
Net Debt Issued (Repaid) | 44.22 | -9.97 | -9.02 | -1.44 | 14.8 |
Common Dividends Paid | -36.05 | -36.05 | -30.05 | -30.05 | -30 |
Other Financing Activities | -6.57 | -17.99 | -12.74 | -13.52 | -10.36 |
Financing Cash Flow | 1.59 | -64.02 | -51.8 | -45.01 | -25.56 |
Net Cash Flow | 81.14 | 76.67 | 6.95 | -18.82 | -45.04 |
Free Cash Flow | 809.31 | 739.86 | 237.41 | 250.03 | 306.07 |
Free Cash Flow Growth | 9.39% | 211.64% | -5.05% | -18.31% | -49.43% |
Free Cash Flow Margin | 11.49% | 11.87% | 4.09% | 4.90% | 6.48% |
Free Cash Flow Per Share | 40.40 | 36.94 | 11.85 | 12.48 | 15.28 |
Cash Interest Paid | - | 17.99 | 12.74 | 13.52 | 10.36 |
Cash Income Tax Paid | - | 263.07 | 261.51 | 296.1 | 236.96 |
Levered Free Cash Flow | 235.01 | 448.04 | 213.14 | 44.59 | 62.93 |
Unlevered Free Cash Flow | 241.35 | 454.26 | 219.05 | 54.82 | 68.68 |
Change in Working Capital | 95.57 | 91.71 | -161.17 | -313.74 | 24.05 |